A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
Phase 1
Recruiting
- Conditions
- Respiratory Infections, Recurrent, ChronicCystic Fibrosis LungPseudomonas Aeruginosa
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Respirion Pharmaceuticals Pty Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06016088
- Locations
- 🇺🇸
Tucson Cystic Fibrosis Center, Tucson, Arizona, United States
🇺🇸Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
© Copyright 2025. All Rights Reserved by MedPath